Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection

about

Progress in HIV vaccine development

P2860

Q56970600-EAC014C4-4592-4F14-90FF-9BFCC8BC3B3E

P2860

Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection

Item

http://www.wikidata.org/entity/Q42386442

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Letter to the Editor on: The R ...... with enhancement of infection

@en

Letter to the Editor on: The R ...... with enhancement of infection

@nl

type

Item

label

Letter to the Editor on: The R ...... with enhancement of infection

@en

Letter to the Editor on: The R ...... with enhancement of infection

@nl

prefLabel

Letter to the Editor on: The R ...... with enhancement of infection

@en

Letter to the Editor on: The R ...... with enhancement of infection

@nl

P1476

Letter to the Editor on: The R ...... with enhancement of infection

@en

P2093

Peter Gilbert

http://www.w3.org/2001/XMLSchema#string

Punnee Pitisuttihum

http://www.w3.org/2001/XMLSchema#string

Robert O'Connell

http://www.w3.org/2001/XMLSchema#string

Sandhya Vasan

http://www.w3.org/2001/XMLSchema#string

Sorachai Nitayapan

http://www.w3.org/2001/XMLSchema#string

P2860

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.

Could vaccination with AIDSVAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects?

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Acceptability of A-CASI by HIV-positive IDUs in a multisite, randomized, controlled trial of behavioral intervention (INSPIRE).

P304

1036-1037

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/21645515.2015.1010970

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273327291

http://www.w3.org/2001/XMLSchema#string

P698

25746053

http://www.w3.org/2001/XMLSchema#string

P932

4514177

http://www.w3.org/2001/XMLSchema#string

Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection

about

P2860

P2860

Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932